Logo image of AVTX

AVALO THERAPEUTICS INC (AVTX) Stock Fundamental Analysis

NASDAQ:AVTX - Nasdaq - US05338F3064 - Common Stock - Currency: USD

8.31  +0.11 (+1.34%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to AVTX. AVTX was compared to 551 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVTX as it has an excellent financial health rating, but there are worries on the profitability. AVTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AVTX has reported negative net income.
In the past year AVTX has reported a negative cash flow from operations.
In the past 5 years AVTX always reported negative net income.
AVTX had a negative operating cash flow in each of the past 5 years.
AVTX Yearly Net Income VS EBIT VS OCF VS FCFAVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of AVTX (-41.34%) is comparable to the rest of the industry.
AVTX has a better Return On Equity (-46.84%) than 66.42% of its industry peers.
Industry RankSector Rank
ROA -41.34%
ROE -46.84%
ROIC N/A
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVTX Yearly ROA, ROE, ROICAVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

With an excellent Gross Margin value of 201.13%, AVTX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Gross Margin of AVTX has grown nicely.
AVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 201.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
AVTX Yearly Profit, Operating, Gross MarginsAVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

AVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AVTX has been increased compared to 1 year ago.
AVTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for AVTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVTX Yearly Shares OutstandingAVTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
AVTX Yearly Total Debt VS Total AssetsAVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -0.38, we must say that AVTX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AVTX (-0.38) is better than 60.80% of its industry peers.
There is no outstanding debt for AVTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.38
ROIC/WACCN/A
WACC10.87%
AVTX Yearly LT Debt VS Equity VS FCFAVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 19.96 indicates that AVTX has no problem at all paying its short term obligations.
AVTX has a better Current ratio (19.96) than 93.47% of its industry peers.
A Quick Ratio of 19.96 indicates that AVTX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 19.96, AVTX belongs to the best of the industry, outperforming 93.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 19.96
Quick Ratio 19.96
AVTX Yearly Current Assets VS Current LiabilitesAVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

AVTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.23%, which is quite impressive.
Looking at the last year, AVTX shows a very negative growth in Revenue. The Revenue has decreased by -77.08% in the last year.
AVTX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -42.05% yearly.
EPS 1Y (TTM)94.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.11%
Revenue 1Y (TTM)-77.08%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%N/A

3.2 Future

AVTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.61% yearly.
The Revenue is expected to grow by 111.61% on average over the next years. This is a very strong growth
EPS Next Y96.62%
EPS Next 2Y40.46%
EPS Next 3Y25.53%
EPS Next 5Y14.61%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y111.61%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AVTX Yearly Revenue VS EstimatesAVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2029 2030 2031 2032 100M 200M 300M
AVTX Yearly EPS VS EstimatesAVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2K -4K -6K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVTX Price Earnings VS Forward Price EarningsAVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVTX Per share dataAVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

AVTX's earnings are expected to grow with 25.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.46%
EPS Next 3Y25.53%

More info and screens

0

5. Dividend

5.1 Amount

AVTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVALO THERAPEUTICS INC

NASDAQ:AVTX (8/6/2025, 4:30:02 PM)

8.31

+0.11 (+1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners62.51%
Inst Owner Change0%
Ins Owners5.85%
Ins Owner Change43.35%
Market Cap90.00M
Analysts88.57
Price Target31.47 (278.7%)
Short Float %1.9%
Short Ratio1.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-946.48%
Min EPS beat(2)-1889.97%
Max EPS beat(2)-2.98%
EPS beat(4)0
Avg EPS beat(4)-3403.42%
Min EPS beat(4)-11614.9%
Max EPS beat(4)-2.98%
EPS beat(8)3
Avg EPS beat(8)-1969.42%
EPS beat(12)5
Avg EPS beat(12)-1307.29%
EPS beat(16)7
Avg EPS beat(16)-984.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.29%
PT rev (3m)-2.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)3.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 204.08
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.73
EV/EBITDA N/A
EPS(TTM)-24.52
EYN/A
EPS(NY)-4.43
Fwd EYN/A
FCF(TTM)-4.53
FCFYN/A
OCF(TTM)-4.53
OCFYN/A
SpS0.04
BVpS12.28
TBVpS11.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.34%
ROE -46.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 201.13%
FCFM N/A
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.96
Quick Ratio 19.96
Altman-Z -0.38
F-Score5
WACC10.87%
ROIC/WACCN/A
Cap/Depr(3y)52.94%
Cap/Depr(5y)33.74%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.11%
EPS Next Y96.62%
EPS Next 2Y40.46%
EPS Next 3Y25.53%
EPS Next 5Y14.61%
Revenue 1Y (TTM)-77.08%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y111.61%
EBIT growth 1Y-96.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-59.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.9%
OCF growth 3YN/A
OCF growth 5YN/A